Lima, Peru.
A Peruvian participant in the eclinical trial with the vaccine against COVID-19 from the Chinese laboratory Sinopharm fhe got sick with pneumonia caused by coronavirus, an event that does not mean that the vaccine is not effectivez, those responsible for the investigation warned Tuesday.
The Universidad Peruana Cayetano Heredia (UPCH), responsible for the study in which the victim, confirmed this Tuesday death of the woman without revealing whether he has it vaccine or in his case he had one placebo, how is it done in this essay class.
6,000 volunteers attended UPCH to participate in the clinical trial of vaccine from Sinopharm, with whom 2,000 were vaccinated vaccine made with the variant of virus SARS-CoV-2 from Wuhan, to another 2,000 that of Beijing and another 2,000 had one placebo.
After receiving the placebo, the woman developed the infectious image from COVID-19 on a regular basis and was complicated by suffer from diabetes and hypertension, two risk factors associated with much of the deaths for this illness in Peru, as indicated by Germán Málaga, principal investigator of the clinical trial.
If you are one of the vaccines againstinvolved in the study, the infection and posterior of the woman may be due to effectiveness of this is not 100%, the UPCH recalled, something that has yet to be confirmed.
MORE THAN A SERIOUS WEEK
The university reported that the volunteer was diagnosed and treated from the onset of the disease, then a early hospitalization and later when his condition passed worst, had access to a mechanical ventilator in an intensive care unit (UCI).
The study and research center noted that “it received everything indicated care to try this illness and their complications and he fought for his life for over a week without the attack it. “
The fatal outcome has been notified to the Security Committee and the competent authorities to notify the research to clarify this episode.
The UPCH also noted that all study volunteers are being advised to proceed with the usual precautions to prevent contamination of the covid-19, as the participants do not know if they have got the vaccine or the placebo.
The clinical trial of Sinopharm vaccine, conducted by UPCH, was shelved by the National Institute of Health (INS) for nearly a week in December after a 64-year-old volunteer completed a series of neurological symptoms, including weakness in the legs, similar to syndrome Guillain Barre.
WAITING FOR THE FIRST VACCINES
The Peruvian government is waiting to receive the first 38 million doses from vaccine from Sinopharm which it has committed to acquire by this year 2021.
Despite the Executive’s announcement first batch of vaccines was supposed to arrive in January, apparently it won’t be after the government administration has not completed the shipment and it has been a group of private companies committed to pay and process the plane what will bring vaccinations
Sinopharm’s is a priori the contract of Peru greater to get vaccines after also agreeing to the purchase 14 million doses to the British laboratory AstraZeneca and have guaranteed 13.3 million doses provided by the multilateral initiative COVAX, all of which should have been added before iimmunize its entire population.
See: Biden wants to vaccinate all Americans at the end of August
However, a recent study has shown that a 48% of Peruvians you don’t want to get the vaccine because you don’t think it will be safe, especially because it has developed so quickly and the normal time limits for clinical trials.
Peru is currently in the middle of the second wave of infections of Covid-19, with his health system collapsed again and the death toll is accelerating every day.
In all, it registers more than a million dand cases symptomatic confirmed, of which nearly 40,000 died, but the reports of the regional governments, which count the cases asymptomatic and suspicious, together they increase the number of cases to more than two million. EFE